Regeneron (REGN) Tops Q2 EPS by $1.18, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Regeneron Reports Second Quarter 2020 Financial and Operating Results
August 5, 2020 6:30 AM EDTTARRYTOWN, N.Y., Aug. 5, 2020 /PRNewswire/ --Â
Second quarter 2020 revenues increased 24% to $1.95 billion versus second quarter 2019(4) Second quarter 2020 EYLEA® U.S. net sales were $1.11 billion Second quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, were $945 million Second quarter 2020 GAAP diluted EPS was $7.61 and non-GAAP diluted EPS(1) was $7.16 Initiated Phase 2 and Phase 3 clinical trials of REGN-COV2 for the treatment and prevention of COVID-19 FDA approved Dupixent for children aged 6 to 11 years with moderate-to-severe atopic dermatitis Dupixent eosinophilic... More